Aspirin increases susceptibility of Helicobacter pylori to metronidazole by augmenting endocellular concentrations of antimicrobials

World Journal of Gastroenterology

Volumn 15, Issue 8, 2009, Pages 919-926

  Zhang, Xiao Ping ^a   Wang, Wei Hong ^a   Tian, Yu ^a   Gao, Wen ^a   Li, Jiang ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Aspirin; Helicobacter pylori; Metronidazole; Minimum inhibitory concentrations; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; BACTERIAL PROTEIN; HOPA PROTEIN; HOPB PROTEIN; HOPC PROTEIN; HOPD PROTEIN; HOPE PROTEIN; METRONIDAZOLE; OUTER MEMBRANE PROTEIN; RDXA PROTEIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL RNA; MESSENGER RNA; NITROREDUCTASE; PRIMER DNA; RDXA PROTEIN, HELICOBACTER PYLORI; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL LEVEL; CONTROLLED STUDY; GENE MUTATION; HELICOBACTER PYLORI; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SEQUENCE ANALYSIS; DRUG EFFECT; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; POLYMERASE CHAIN REACTION;

ANTI-INFECTIVE AGENTS; ASPIRIN; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; DNA PRIMERS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, BACTERIAL; HELICOBACTER PYLORI; METRONIDAZOLE; NITROREDUCTASES; POLYMERASE CHAIN REACTION; RNA, BACTERIAL; RNA, MESSENGER; TETRACYCLINE;

EID: 65649148587     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.919     Document Type: Article

References (43)

1. Kagawa A, Azuma H, Akaike M, Kanagawa Y, Matsumoto T. Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 1999; 274: 34111-34115
2. Morgan G. Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers. Gut 1996; 38: 646-648
3. Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996; 41: 1319-1326
4. Vainio H, Morgan G, Kleihues P. An international evaluation of the cancer-preventive potential of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 1997; 6: 749-753
5. Price CT, Lee IR, Gustafson JE. The effects of salicylate on bacteria. Int J Biochem Cell Biol 2000; 32: 1029-1043
6. Wang WH, Hu FL, Wong BCY, Berg DE, Lam SK. Inhibitory effects of aspirin and indometacin on the growth of Helicobacter pylori in vitro. Chin J Dig Dis 2002; 3: 172-177
7. Wang WH, Wong WM, Dailidiene D, Berg DE, Gu Q, Lai KC, Lam SK, Wong BC. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 2003; 52: 490-495
8. Gu Q, Xia HH, Wang WH, Wang JD, Wong WM, Chan AO, Yuen MF, Lam SK, Cheung HK, Liu XG, Wong BC. Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. Aliment Pharmacol Ther 2004; 20: 675-681
9. Ma HX, Wang WH, Hu FL, Li J. Effect of aspirin and celecoxib on Helicobacter pylori in vitro. Shijie Huaren Xiaohua Zazhi 2006; 14: 2747-2752
10. Walker MM, Crabtree JE. Helicobacter pylori infection and the pathogenesis of duodenal ulceration. Ann N Y Acad Sci 1998; 859: 96-111
11. Telford J L, Covacci A, Rappuoli R, Chiara P. Immunobiology of Helicobacter pylori infection. Curr Opin Immunol 1997; 9: 498-503
12. Vandenplas Y. Helicobacter pylori infection. World J Gastroenterol 2000; 6: 20-31
13. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000; 118: S2-S8
14. Kunin CM, Hua TH, Guerrant RL, Bakaletz LO. Effect of salicylate, bismuth, osmolytes, and tetracycline resistance on expression of fimbriae by Escherichia coli. Infect Immun 1994; 62: 2178-2186
15. Farber BF, Wolff AG. The use of salicylic acid to prevent the adherence of Escherichia coli to silastic catheters. J Urol 1993; 149: 667-670
16. Kunin CM, Hua TH, Bakaletz LO. Effect of salicylate on expression of flagella by Escherichia coli and Proteus, Providencia, and Pseudomonas spp. Infect Immun 1995; 63: 1796-1799
17. Farber BF, Hsieh HC, Donnenfeld ED, Perry HD, Epstein A, Wolff A. A novel antibiofilm technology for contact lens solutions. Ophthalmology 1995; 102: 831-836
18. Muller E, Al-Attar J, Wolff AG, Farber BF. Mechanism of salicylate-mediated inhibition of biofilm in Staphylococcus epidermidis. J Infect Dis 1998; 177: 501-503
19. Teichberg S, Farber BF, Wolff AG, Roberts B. Salicylic acid decreases extracellular biofilm production by Staphylococcus epidermidis: electron microscopic analysis. J Infect Dis 1993; 167: 1501-1503
20. Domenico P, Schwartz S, Cunha BA. Reduction of capsular polysaccharide production in Klebsiella pneumoniae by sodium salicylate. Infect Immun 1989; 57: 3778-3782
21. Salo RJ, Domenico P, Tomás JM, Straus DC, Merino S, Benedí VJ, Cunha BA. Salicylate-enhanced exposure of Klebsiella pneumoniae subcapsular components. Infection 1995; 23: 371-377
22. Rosner JL. Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in Escherichia coli K-12. Proc Natl Acad Sci USA 1985; 82: 8771-8774
23. Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother 1989; 33: 1318-1325
24. Sulavik MC, Dazer M, Miller PF. The Salmonella typhimurium mar locus: molecular and genetic analyses and assessment of its role in virulence. J Bacteriol 1997; 179: 1857-1866
25. Domenico P, Hopkins T, Cunha BA. The effect of sodium salicylate on antibiotic susceptibility and synergy in Klebsiella pneumoniae. J Antimicrob Chemother 1990; 26: 343-351
26. Gustafson JE, Candelaria PV, Fisher SA, Goodridge JP, Lichocik TM, McWilliams TM, Price CT, O'Brien FG, Grubb WB. Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 990-992
27. Price CT, O'Brien FG, Shelton BP, Warmington JR, Grubb WB, Gustafson JE. Effects of salicylate and related compounds on fusidic acid MICs in Staphylococcus aureus. J Antimicrob Chemother 1999; 44: 57-64
28. Domenico P, Straus DC, Woods DE, Cunha BA. Salicylate potentiates amikacin therapy in rodent models of Klebsiella pneumoniae infection. J Infect Dis 1993; 168: 766-769
29. Aumercier M, Murray DM, Rosner JL. Potentiation of susceptibility to aminoglycosides by salicylate in Escherichia coli. Antimicrob Agents Chemother 1990; 34: 786-791
30. Messier N, Roy PH. Integron integrases possess a unique additional domain necessary for activity. J Bacteriol 2001; 183: 6699-6706
31. Edwards DI. Nitroimidazole drugs - action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 1993; 31: 9-20
32. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten SJ, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 1998; 28: 383-393
33. Jenks PJ, Edwards DI. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents 2002; 19: 1-7
34. Mendz GL, Mégraud F. I s the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol 2002; 10: 370-375
35. Ma D, Cook DN, Alberti M, Pon NG, Nikaido H, Hearst JE. Genes acrA and acrB encode a stress-induced efflux system of Escherichia coli. Mol Microbiol 1995; 16: 45-55
36. Fralick JA. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J Bacteriol 1996; 178: 5803-5805
37. Rosner JL, Chai TJ, Foulds J. Regulation of ompF porin expression by salicylate in Escherichia coli. J Bacteriol 1991; 173: 5631-5638
38. Hancock RE. The bacterial outer membrane as a drug barrier. Trends Microbiol 1997; 5: 37-42
39. Doig P, Exner MM, Hancock RE, Trust TJ. Isolation and characterization of a conserved porin protein from Helicobacter pylori. J Bacteriol 1995; 177: 5447-5452
40. Exner MM, Doig P, Trust TJ, Hancock RE. Isolation and characterization of a family of porin proteins from Helicobacter pylori. Infect Immun 1995; 63: 1567-1572
41. Bina JE, Nano F, Hancock RE. Utilization of alkaline phosphatase fusions to identify secreted proteins, including potential efflux proteins and virulence factors from Helicobacter pylori. FEMS Microbiol Lett 1997; 148: 63-68
42. Bina JE, Alm RA, Uria-Nickelsen M, Thomas SR, Trust TJ, Hancock RE. Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother 2000; 44: 248-254
43. Park SH, Park DI, Kim SH, Kim HJ, Cho YK, Sung IK, Sohn CI, Jeon WK, Kim BI, Keum DK. Effect of high-dose aspirin on Helicobacter pylori eradication. Dig Dis Sci 2005; 50: 626-629